Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 10/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886004 | 0.85 | CAPN1 (0.48) | KMT2A | |
| SCHEMBL22886638 | 0.82 | PYGL (0.43) | PYGLCCR1RAB9AKMT2AMEN1 | |
| SCHEMBL22886609 | 0.82 | PYGL (0.45) | PYGLCCR1EGLN2EGLN1HPGDS | |
| SCHEMBL20028423 | 0.78 | CDC7 (0.42) | PYGLCCR1HPGDS | |
| SCHEMBL20028429 | 0.77 | PYGL (0.42) | PYGLCCR1KMT2AHPGDS | |
| SCHEMBL20028432 | 0.77 | PYGL (0.37) | PYGLCCR1RAB9ATHRB | |
| SCHEMBL20028427 | 0.76 | PYGL (0.41) | PYGLCCR1EGLN2EGLN1HPGDS | |
| SCHEMBL20028424 | 0.75 | PYGL (0.40) | PYGLCCR1HPGDS | |
| SCHEMBL22886421 | 0.74 | PYGL (0.38) | PYGLCCR1RAB9AKMT2AMEN1 | |
| SCHEMBL22886770 | 0.73 | PYGL (0.38) | PYGLCCR1RAB9AEGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | PYGL 719/4885CCR1 3791/4885RAB9A 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.